BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38583573)

  • 1. Genomic characterization of carbapenemase-producing Klebsiella pneumoniae ST307 revealed multiple introductions in Buenos Aires, Argentina.
    González-Espinosa F; Di Pilato V; Magariños F; Di Conza J; Rossolini GM; Gutkind G; Radice M; Cejas D
    J Glob Antimicrob Resist; 2024 Jun; 37():176-178. PubMed ID: 38583573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307.
    Cejas D; Elena A; Guevara Nuñez D; Sevillano Platero P; De Paulis A; Magariños F; Alfonso C; Berger MA; Fernández-Canigia L; Gutkind G; Radice M
    J Glob Antimicrob Resist; 2019 Sep; 18():238-242. PubMed ID: 31202977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
    Piazza A; Mattioni Marchetti V; Bielli A; Biffignandi GB; Piscopiello F; Giudici R; Tartaglione L; Merli M; Vismara C; Migliavacca R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):457-469. PubMed ID: 38584042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-depth characterization of multidrug-resistant NDM-1 and KPC-3 co-producing
    Posteraro B; De Maio F; Motro Y; Menchinelli G; De Lorenzis D; Marano RBM; Aljanazreh B; Errico FM; Massaria G; Spanu T; Posteraro P; Moran-Gilad J; Sanguinetti M
    Microbiol Spectr; 2024 Apr; 12(4):e0330523. PubMed ID: 38411998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
    Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging high-risk ST101 and ST307 carbapenem-resistant Klebsiella pneumoniae clones from bloodstream infections in Southern Italy.
    Loconsole D; Accogli M; De Robertis AL; Capozzi L; Bianco A; Morea A; Mallamaci R; Quarto M; Parisi A; Chironna M
    Ann Clin Microbiol Antimicrob; 2020 Jun; 19(1):24. PubMed ID: 32487201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
    Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KPC-2 allelic variants in
    Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
    Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
    Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
    Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.